NGD 2000-1: Phase IIa data

In a double-blind, placebo-controlled, U.S. Phase IIa trial in 49 patients with mild to moderate RA, NGD 2000-1 missed the primary endpoint of change in CRP. NGD 2000-1 showed positive trends in some ...